Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Severe organ involvement in systemic sclerosis with diffuse scleroderma.

V D Steen1, T A Medsger

  • 1Georgetown University, Washington, DC 20007-2197, USA.

Arthritis and Rheumatism
|November 18, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

There is a need for new systemic sclerosis subset criteria. A content analytic approach.

Scandinavian journal of rheumatology·2017
Same author

SYSTEMIC SCLEROSIS RELATED CALCINOSIS: PATIENTS PROVIDE WHAT SPECIALISTS WANT TO LEARN.

The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society·2016
Same author

Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters.

Clinical and experimental rheumatology·2014
Same author

Endothelial dysfunction is present only in the microvasculature and microcirculation of early diffuse systemic sclerosis patients.

Clinical and experimental rheumatology·2014
Same author

Recognition of pulmonary hypertension in the rheumatology community: lessons from a Quality Enhancement Research Initiative.

Clinical and experimental rheumatology·2013
Same author

Is exercise-induced pulmonary hypertension ready for prime time in systemic sclerosis?

International journal of clinical practice. Supplement·2010
Same journal

Proceedings of the Annual Meeting of the American Rheumatism Association.

Arthritis and rheumatism·2020
Same journal

The regional distribution of rheumatologists: what can we do, what should we do?

Arthritis and rheumatism·2013
Same journal

Regional distribution of adult rheumatologists.

Arthritis and rheumatism·2013
Same journal

Clinically significant renal involvement in primary Sjögren's syndrome: clinical presentation and outcome.

Arthritis and rheumatism·2013
Same journal

Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study.

Arthritis and rheumatism·2013
Same journal

Association of low baseline levels of erythrocyte folate with treatment nonresponse at three months in rheumatoid arthritis patients receiving methotrexate.

Arthritis and rheumatism·2013
See all related articles

Severe organ damage in systemic sclerosis (SSc) often occurs within the first three years, significantly reducing patient survival. Early monitoring and intervention are crucial for managing SSc and improving outcomes.

Area of Science:

  • Rheumatology
  • Internal Medicine
  • Clinical Research

Background:

  • Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by fibrosis of the skin and internal organs.
  • Diffuse cutaneous involvement in SSc is associated with a higher risk of severe organ damage.
  • Understanding the natural history and timing of organ involvement is critical for patient management.

Purpose of the Study:

  • To investigate the natural history and timing of severe kidney, heart, lung, gastrointestinal (GI), and skin involvement in patients with diffuse systemic sclerosis.
  • To determine the impact of severe organ involvement on patient survival.

Main Methods:

  • Retrospective analysis of 953 patients with diffuse SSc from the Pittsburgh Scleroderma Databank (1972-1995).
  • Defined severe organ involvement criteria for kidney (renal crisis), heart (cardiomyopathy, etc.), lung (fibrosis, low FVC), GI tract (malabsorption, etc.), and skin (high skin score).

Related Experiment Videos

  • Determined the time from disease onset to severe organ involvement and calculated survival rates.

    • Main Results:

    • Severe skin (24%) and kidney (19%) involvement occurred within 3 years in 70% of affected patients.
    • Severe heart (15%), lung (16%), and GI (8%) involvement occurred within 3 years in 45-55% of affected patients.
    • Nine-year survival was 38% for patients with severe organ involvement versus 72% for those without (P < 0.0001).

    Conclusions:

    • Severe organ damage in diffuse SSc predominantly manifests early in the disease course.
    • Early identification and management of organ involvement are essential to improve survival in SSc patients.
    • Patients surviving the initial years without severe involvement have a better long-term prognosis.